研究单位:[1]Hebei Medical University Fourth Hospital河北医科大学第四医院
研究目的:
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus radiotherapy and S-1 for treatment of refractory or metastatic esophageal squamous cell carcinoma.